Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer

Table 1 Baseline characteristics and neoadjuvant therapy, median (interquartile range)/n (%)

Variable	PAC group (n = 92)	PC group (n = 200)	Statistic	P value
Age, years	64 (56-69)	63 (55-67)	-1.557	0.119
Sex			0.021	0.885
Female	20 (21.7)	45 (22.5)
Male	72 (78.3)	155 (77.5)
BMI, kg/m2	22.7 (20.7-25.1)	23.4 (21.7-25.6)	-1.860	0.063
ASA score			0.256	0.613
1-2	12 (13.0)	22 (11.0)
≥ 3	80 (87.0)	178 (89.0)
ECOG performance status score			0.940	0.332
0-1	86 (93.5)	180 (90.0)
2	6 (6.5)	20 (10.0)
NRS 2002 score			0.589	0.443
< 3	68 (73.9)	156 (78.0)
≥ 3	24 (26.1)	44 (22.0)
cT stage			3.049	0.218
T3	29 (31.5)	44 (22.0)
T4a	43 (46.7)	106 (53.0)
T4b	20 (21.7)	50 (25.0)
cN stage			0.233	0.629
N0-1	30 (32.6)	71 (35.5)
N2-3	62 (67.4)	129 (64.5)
cTNM stage			0.886	0.642
II	21 (22.8)	37 (18.5)
III	51 (55.4)	113 (56.5)
IV	20 (21.7)	50 (25.0)
Tumor location			2.317	0.314
Upper third	29 (31.5)	62 (31.0)
Middle third	34 (37.0)	90 (45.0)
Lower third	29 (31.5)	48 (24.0)
Tumor histological differentiation			2.739	0.254
Well	14 (15.2)	41 (20.5)
Moderate	34 (37.0)	83 (41.5)
Poor	44 (47.8)	76 (38.0)
Tumor pathological type			0.090	0.764
Adenocarcinoma	86 (93.5)	185 (92.5)
Signet ring cell carcinoma	6 (6.5)	15 (7.5)
Lauren type			1.191	0.755
Intestinal	21 (22.8)	48 (24.0)
Mixed	32 (34.8)	78 (39.0)
Diffused	28 (30.4)	49 (24.5)
Indeterminate	11 (12.0)	25 (12.5)
Bormann type			3.400	0.334
I	2 (2.2)	14 (7.0)
II	69 (75.0)	149 (74.5)
III	14 (15.2)	23 (11.5)
IV	7 (7.6)	14 (7.0)
HER-2 positive	8 (8.7)	29 (14.5)	1.919	0.166
dMMR	8 (8.7)	7 (3.5)		0.085
Ki-67 expression rate, %	60 (40-70)	60 (30-70)	-1.074	0.283
Lymphovascular invasion	34 (37.4)	84 (42.0)	0.558	0.455
Perineural invasion	22 (24.2)	68 (34.2)	2.915	0.088
Preoperative therapy cycles	3 (2-4)	3 (2-4)	-0.771	0.441
Treatment-related adverse events	24 (26.1)	40 (20.0)	1.364	0.243

Percentages may not sum to 100% due to rounding. PAC: Programmed cell death protein-1 inhibitors plus apatinib and chemotherapy; PC: Preoperative chemotherapy; ASA: American Society Anesthesiologists; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; NRS: Nutritional Risk Screening; HER-2: Human epidermal growth factor receptor-2; dMMR: Mismatch repair deficiency; TNM: Tumor node metastasis.